Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development
28 Fevereiro 2023 - 9:00AM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage
biotechnology company committed to discovering and delivering the
next generation of precision cancer medicines, today announced the
appointment of Adam Crystal, M.D., Ph.D. as President of Research
and Development. In this executive leadership role, Dr. Crystal
will oversee all phases of preclinical research, drug discovery and
clinical development. Alan Huang, Ph.D., Chief Scientific Officer,
and Ron Weitzman, M.D., Ph.D., Chief Medical Officer, will
continue to lead the research and clinical development functions,
respectively, as members of Dr. Crystal’s team.
“Adam is joining at a pivotal time, as we are actively enrolling
patients in the dose escalation phase of our first clinical trial
and plan to advance three more programs into the clinic over the
coming year,” said Barbara Weber, M.D., President and Chief
Executive Officer of Tango Therapeutics. “Adam’s deep understanding
of precision oncology, coupled with his successful track record in
both research and clinical leadership, will be instrumental in
advancing our pipeline.”
“I’m impressed by the experienced research and development teams
at Tango and the compelling and innovative programs they have
discovered and developed,” said Dr. Crystal. “I look forward to
working with the team to execute on these opportunities as we bring
the promise of synthetic lethal drug targeting to patient
populations with significant medical need.”
Most recently, Dr. Crystal served as Chief Medical Officer of C4
Therapeutics where he oversaw the advancement of several oncology
drug candidates into clinical trials. Prior to that, Dr. Crystal
was at Novartis Oncology where he led multiple early clinical
development programs. Dr. Crystal has served as a medical
oncologist at Massachusetts General Hospital where he studied
resistance mechanisms to targeted therapies. He completed his
internal medicine training at Massachusetts General Hospital and
his fellowship in medical oncology at the Massachusetts General
Hospital Cancer Center and the Dana-Farber Cancer Institute. Dr.
Crystal holds an M.D., as well as a Ph.D. in Neuroscience from the
University of Pennsylvania School of Medicine.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company
dedicated to discovering novel drug targets and delivering the next
generation of precision medicine for the treatment of cancer. Using
an approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered
forward-looking statements. Forward-looking statements generally
relate to future events, Tango’s future operating performance and
goals, the anticipated benefits of therapies and combination
therapies (that include a Tango pipeline product), expectations,
beliefs and development objectives for Tango’s product pipeline and
clinical trials. In some cases, you can identify forward-looking
statements by terminology such as “may”, “should”, “expect”,
“intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these
terms or variations of them or similar terminology. For example,
statements concerning the following include or constitute
forward-looking statements: Tango continues to actively enroll
patients in our TNG908 Phase 1/2 clinical trial; Tango expects to
advance three more programs (in addition to TNG908) into the clinic
over the next year; Dr. Crystal will be instrumental in advancing
our synthetic lethal pipeline; Tango two additional INDs planned
for 2023; Tango has the opportunity to bring the promise of
synthetic lethal drug targeting to patient populations with
significant medical need; the expected benefits of the Company's
development candidates and other product candidates; and the
expected timing of: (i) development candidate declaration for
certain targets, (ii) initiating IND-enabling studies; (iii) filing
INDs; (iv) clinical trial initiation and (v) disclosing initial and
final clinical trial results. Such forward-looking statements are
subject to risks, uncertainties, and other factors which could
cause actual results to differ materially from those expressed or
implied by such forward looking statements. These forward-looking
statements are based upon estimates and assumptions that, while
considered reasonable by Tango and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: Tango has limited experience conducting clinical trials (and
will rely on a third party to operate its clinical trials) and may
not be able to commence the clinical trial (including opening
clinical trial sites and enrolling and dosing an adequate number of
clinical trial participants) when expected and may not generate
results (including final or initial safety and efficacy data) in
the anticipated timeframe (or at all); benefits of product
candidates seen in preclinical analyses may not be evident when
tested in clinical trials or when used in broader patient
populations (if approved for commercial sale); the loss of key
personnel or the expected contributions to be made by employees on
advancing product candidates may not be realized in the timeframe
anticipated or at all; the benefits of Tango pipeline products,
development candidates and potential combination therapies that are
seen in pre-clinical experiments may not be present in clinical
trials or in use commercially or may not be safe and/or effective
in humans; Tango has a limited operating history and has not
generated any revenue to date from product sales, and may never
become profitable; other companies may be able to identify and
develop product candidates more quickly than the Company and
commercially introduce the product prior to the Company; the
Company’s proprietary discovery platform is novel and may not
identify any synthetic lethal targets for future development; the
Company may not be able to identify development candidates on the
schedule it anticipates due to technical, financial or other
reasons; the Company may not be able to file INDs for development
candidates or advance therapies into clinical trials on time, or at
all, due to technical or financial reasons or otherwise; the
Company may utilize cash resources more quickly than anticipated;
Tango will need to raise capital in the future and if we are unable
to raise capital when needed or on attractive terms, we would be
forced to delay, scale back or discontinue some of our development
programs or future commercialization efforts; we may be unable to
advance our preclinical development programs into and through the
clinic for safety or efficacy reasons or commercialize our product
candidates or we may experience significant delays in doing so as a
result of factors beyond Tango’s control;; Tango’s approach to the
discovery and development of product candidates is novel and
unproven, which makes it difficult to predict the time, cost of
development, and likelihood of successfully developing any
products; Tango may not identify or discover additional product
candidates or may expend limited resources to pursue a particular
product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which
there is a greater likelihood of success; our products candidates
may cause adverse or other undesirable side effects (or may not
show requisite efficacy) that could, among other things, delay or
prevent regulatory approval; our dependence on third parties for
conducting clinical trials and producing drug product; our ability
to obtain and maintain patent and other intellectual property
protection for our technology and product candidates or the scope
of intellectual property protection obtained is not sufficiently
broad; and delays and other impacts on product development and
clinical trials from the COVID-19 pandemic. Additional information
concerning risks, uncertainties and assumptions can be found in
Tango’s filings with the SEC, including the risk factors referenced
in Tango’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, as supplemented and/or modified by its most
recent Quarterly Report on Form 10-Q. You should not place undue
reliance on forward-looking statements in this presentation, which
speak only as of the date they are made and are qualified in their
entirety by reference to the cautionary statements herein. Tango
specifically disclaims any duty to update these forward-looking
statements. Investor Contact:Sam
Martin/Andrew VulisArgot Partnerstango@argotpartners.com
Media Contact:Joshua R. Mansbach Argot Partners
tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024